Karim Chamie, MD, reviews a high-risk muscle invasive bladder cancer case and highlights potential treatment options.
EP. 1: Case Overview: A 75-Year-Old Woman with High-Risk Muscle Invasive Bladder Cancer
Karim Chamie, MD, presents the case of a 75-year-old woman with high-risk muscle invasive bladder cancer.
EP. 2: Standard of Care for Muscle-Invasive Bladder Cancer
Dr. Karim Chamie details the available primary and adjuvant treatments for muscle invasive bladder cancer.
EP. 3: Adjuvant Nivolumab for High-Risk Muscle-Invasive Bladder Cancer
An oncologist reviews the use of nivolumab in the adjuvant setting for treating high-risk muscle invasive bladder cancer and experience from his practice.
EP. 4: Ongoing Clinical Trials in Muscle-Invasive Bladder Cancer
A bladder cancer expert several ongoing clinical trials in the neoadjuvant and adjuvant setting.
EP. 5: The Future of Treatments for Muscle Invasive Bladder Cancer
Karim Chamie, MD, describes what treatments might be on the horizon for muscle invasive bladder cancer and provides some clinical pearls to manage patients with MIBC.
Intraprostatic drug elution therapy shows promise for BPH-related LUTS
Subcutaneous nivolumab approved in EU, Canada for solid tumors
Phase 3 trial of tebipenem HBr for cUTI stopped early for efficacy
Application submitted to FDA for 510(k) clearance of Men’s Sexual Health Test